Treatment of refractory obesity with fenfluramine.

Munro, James; Seaton, D. A.; Duncan, L. J. P.

doi:10.1136/bmj.2.5514.624

Cited by 75 publications

(33 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fenfluramine (3-trifluoromethyl-N-ethylamphetamine), a derivate of amphetamine, was recognized as an appetite suppressant in the mid-1960s [Munro et al 1966] and approved for this indication in the US in 1973. As a derivative of amphetamine, the anorectic effect was believed to be exercised through serotoninergic mechanisms.…”

Section: Fenfluraminementioning

confidence: 99%

Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome

Schoonjans

Lagae

Ceulemans

2015

Ther Adv Neurol Disord

View full text Add to dashboard Cite

In this paper, we review the experience with fenfluramine in epileptic and other paroxysmal disorders. Since the best available data are from the treatment of Dravet syndrome, we will focus primarily on this condition. Originally fenfluramine was launched as an anorectic agent. As early as 1985, seizure reduction in children could be demonstrated in a few cases with photosensitive, self-induced epilepsy. Hereafter, a small study was launched in patients with self-induced epilepsy. Results showed a significant seizure reduction, and review of the patient data showed that 5 of the 12 patients had Dravet syndrome. During that observation period, fenfluramine was withdrawn from the market because of cardiovascular side effects associated with prescribing higher doses in combination with phentermine for weight loss. In March 2002, a Belgian Royal Decree was issued permitting further study of fenfluramine in pediatric patients with intractable epilepsy. In 2011 under the Royal Decree, a prospective study of patients with Dravet syndrome treated with low-dose fenfluramine was initiated and is currently ongoing. The initial results are promising in terms of reduction of seizure frequency and overall tolerability.

show abstract

Section: Fenfluraminementioning

confidence: 99%

Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome

Schoonjans

Lagae

Ceulemans

2015

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…However it has been reported that some patients on the drug complain of frequency of bowel motions amounting to diarrhoea. The incidence of diarrhoea reported by Munro et al (1966), Hollingsworth and Amatruda (1969) and Sedgwick (1972) was 40, 44 and 67%/ respectively. The cause of this diarrhoea consecutive to the treatment with fenfluramine is obscure.…”

Section: Introductionmentioning

confidence: 90%

“…Controlled trials on the use of appetite suppressants such as amphetamines have shown a variety ofundesirable side effects including central nervous stimulation, addiction, toxicity, euphoria and even ineffectiveness. The use of amphetamines has been discouraged but fenfluramine, an analogue of amphetamine, has become widely used as an anti-obesity agent devoid of central nervous stimulation (Munro, Seaton and Duncan, 1966;Le Douarec and Niven, 1970). There are reports of its beneficial effects on hyperlipidaemia (Pawan, 1969;Bliss, Kirk and Newall, 1972), on hypercholesterolaemia (Tomlinson, Lines and Greenfield, 1975), and on hyperglycaemia (Turtle, 1972).…”

Section: Introductionmentioning

confidence: 99%

Bile acid, neutral sterol and faecal fat excretion in subjects treated with fenfluramine and its relationship to fenfluramine-induced diarrhoea

Sian

Rains

1979

Postgraduate Medical Journal

View full text Add to dashboard Cite

SummaryBile acid, neutral sterol and faecal fat excretion was studied over a period of 9 weeks in a group of 16 healthy subjects before, during and after administration of fenfluramine. Statistical analysis revealed a significant increase in bile acid excretion during the drug phase (P<0.02); and during recovery period of 3 weeks (P< 0-05). Faecal neutral sterol, as the total of coprostanol and cholesterol elimination was also enhanced after fenfluramine. Coprostanol was replaced by cholesterol in 12 subjects. Faecal fat was studied in 6 subjects, the excretion increased during the drug phase (P< 005), and remained elevated during the post-drug period (P< 001). The composition of the bile acids remained unaltered in all the subjects except 3 who had a fenfluramine-induced watery diarrhoea; and these excreted chenodeoxy and cholic together with smaller amounts of secondary bile acids. A higher excretion of bile acids was found in the 8 overweight subjects (P<0.01) before ministration of fenfluramine.These results are discussed in an attempt to correlate the effect of fenfluramine with changes in bile acid and neutral sterol excretion, and its relationship to fenfluramine-induced diarrhoea.

show abstract

“…The weight loss attributable to zimelidine was 3.14% or 2.5 kg over the 8 week period. This compares with figures of 3-4 kg over 8 weeks for marketed appetite suppressants (see e.g., Munro, Seaton & Duncan, 1966).…”

Section: Plasma Drug Levels and Compliancementioning

confidence: 99%

Effect of zimelidine, a new antidepressant, on appetite and body weight.

Simpson¹,

Lawton²,

Watt³

et al. 1981

Brit J Clinical Pharma

View full text Add to dashboard Cite

LETTERS TO THE EDITORS vivo only, whereas in vitro, it has no influence (Storstein, 1977). In order to rule out the possibility of an indirect effect of quinidine, occurring only in vivo, we compared the binding of digoxin in patients on long-term digoxin treatment with and without concomitant quinidine medication. The results (Table 2) indicate that the in vivo binding of digoxin did not differ between the two groups. It is concluded that serum protein binding of digoxin is not involved in the digoxin-quinidine interaction.

show abstract

Treatment of refractory obesity with fenfluramine.

Cited by 75 publications

References 3 publications

Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome

Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome

Bile acid, neutral sterol and faecal fat excretion in subjects treated with fenfluramine and its relationship to fenfluramine-induced diarrhoea

Effect of zimelidine, a new antidepressant, on appetite and body weight.

Contact Info

Product

Resources

About